Zynerba Pharmaceuticals (ZYNE) Stock Falls -37.8% This Month; What’s Next?


Zynerba Pharmaceuticals (ZYNE) stock is down -37.8% over the past 30 days. ZYNE stock has gained 56.77% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 57 out of a possible 100.

That score is primarily influenced by a fundamental score of 81. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $22.50. This means analysts expect the stock to rise 134.13% over the next 12 months. ZYNE’s score also includes a short-term technical score of 48. The long-term technical score for ZYNE is 42.

Click Here to get the full Stock Score Report on Zynerba Pharmaceuticals Inc (ZYNE).

What’s Happening with ZYNE Stock Today

Zynerba Pharmaceuticals Inc (ZYNE) stock is lower by -5.45% while the S&P 500 has fallen -2.31% as of 12:15 PM on Monday, Aug 5. ZYNE has fallen -$0.55 from the previous closing price of $10.16 on volume of 600,367 shares. Over the past year the S&P 500 is higher by 0.48% while ZYNE has gained 56.77%. ZYNE lost -$2.61 per share in the over the last 12 months.

Symbols: ZYNE

You May Also Like